| 2026 |
| 03/09 | 185 | 190 | 179 | 187 | -3.11% | 318,000 | 69億665万 | -6.03% |
| 03/06 | 186 | 197 | 186 | 193 | +1.05% | 292,800 | 71億2826万 | -3.02% |
| 03/05 | 189 | 197 | 186 | 191 | +5.52% | 432,500 | 70億5439万 | -3.54% |
| 03/04 | 190 | 197 | 178 | 181 | -10.4% | 967,500 | 66億8505万 | -8.12% |
| 03/03 | 209 | 214 | 202 | 202 | -2.42% | 413,900 | 74億6066万 | +2.54% |
| 03/02 | 213 | 215 | 203 | 207 | -5.91% | 484,800 | 76億4533万 | +5.08% |
| 02/27 | 195 | 221 | 195 | 220 | +12.82% | 1,043,700 | 81億2548万 | +12.24% |
| 02/26 | 197 | 201 | 193 | 195 | -1.02% | 319,400 | 72億213万 | 0% |
| 02/25 | 203 | 206 | 193 | 197 | -3.9% | 394,900 | 72億7599万 | +1.03% |
| 02/24 | 202 | 208 | 192 | 205 | +0.49% | 353,800 | 75億7147万 | +5.13% |
| 02/20 | 229 | 229 | 198 | 204 | -7.69% | 1,017,700 | 75億3453万 | +5.15% |
| 02/19 | 227 | 232 | 219 | 221 | -3.49% | 342,800 | 81億6241万 | +14.51% |
| 02/18 | 218 | 239 | 216 | 229 | +7.01% | 1,474,400 | 84億5788万 | +19.9% |
| 02/17 | 217 | 221 | 208 | 214 | -0.93% | 922,600 | 79億387万 | +13.23% |
| 02/16 | 184 | 217 | 183 | 216 | +12.5% | 1,434,900 | 79億7774万 | +14.89% |
| 02/13 | 16:30 営業外収益及び特別損失の計上に関するお知らせ |
| 02/13 | 16:30 2026年9月期第1四半期決算短信〔日本基準〕(非連結) |
| 02/13 | 200 | 200 | 192 | 192 | -3.52% | 391,600 | 70億9132万 | +3.23% |
| 02/12 | 194 | 203 | 193 | 199 | +2.58% | 524,600 | 73億4986万 | +7.57% |
| 02/10 | 187 | 196 | 187 | 194 | +4.3% | 256,900 | 71億6519万 | +5.43% |
| 02/09 | 187 | 187 | 181 | 186 | 0% | 222,200 | 68億6972万 | +2.2% |
| 02/06 | 187 | 189 | 183 | 186 | -3.13% | 337,300 | 68億6972万 | +2.76% |
| 02/05 | 190 | 197 | 190 | 192 | +0.52% | 195,800 | 70億9132万 | +6.67% |
| 02/04 | 192 | 192 | 188 | 191 | 0% | 173,100 | 70億5439万 | +7.3% |
| 02/03 | 186 | 194 | 185 | 191 | +3.24% | 357,300 | 70億5439万 | +7.91% |
| 02/02 | 189 | 192 | 184 | 185 | -3.14% | 198,500 | 68億3279万 | +5.71% |
| 01/30 | 185 | 192 | 184 | 191 | +3.8% | 412,800 | 70億5439万 | +9.77% |
| 01/29 | 179 | 189 | 174 | 184 | +5.75% | 406,400 | 67億9585万 | +6.36% |
| 01/28 | 178 | 179 | 172 | 174 | -3.87% | 390,400 | 64億2651万 | +1.16% |
| 01/27 | 180 | 182 | 178 | 181 | 0% | 127,500 | 66億8505万 | +5.23% |
| 01/26 | 186 | 188 | 181 | 181 | -4.74% | 272,300 | 66億8505万 | +5.85% |
| 01/23 | 186 | 194 | 182 | 190 | +3.26% | 311,000 | 70億1746万 | +12.43% |
| 01/22 | 194 | 195 | 181 | 184 | -3.66% | 535,500 | 67億9585万 | +10.18% |
| 01/21 | 16:00 PRISM BioLabとエーザイが共同創出したE7386、ESMO OPEN 誌にて第I相臨床試験結果に関する学術論文が発表される |
| 01/21 | 197 | 197 | 187 | 191 | -3.54% | 335,000 | 70億5095万 | +15.06% |
| 01/20 | 193 | 198 | 186 | 198 | -1.49% | 704,500 | 73億936万 | +20% |
| 01/19 | 195 | 207 | 189 | 201 | +8.65% | 1,192,000 | 74億2011万 | +23.31% |
| 01/16 | 189 | 191 | 180 | 185 | +3.35% | 685,500 | 68億2946万 | +14.2% |
| 01/15 | 168 | 181 | 166 | 179 | +5.92% | 462,300 | 66億796万 | +10.49% |
| 01/14 | 171 | 176 | 167 | 169 | -1.74% | 400,000 | 62億3880万 | +4.32% |
| 01/13 | 178 | 179 | 170 | 172 | -3.37% | 361,700 | 63億4955万 | +6.17% |
| 01/09 | 179 | 185 | 176 | 178 | -1.11% | 374,400 | 65億7104万 | +9.2% |
| 01/08 | 169 | 182 | 167 | 180 | +7.78% | 886,800 | 66億4488万 | +10.43% |
| 01/07 | 161 | 169 | 160 | 167 | +5.7% | 349,500 | 61億6497万 | +1.21% |
| 01/06 | 160 | 162 | 157 | 158 | -1.86% | 246,100 | 58億3272万 | -4.82% |
| 01/05 | 156 | 163 | 156 | 161 | +3.21% | 201,000 | 59億4347万 | -3.01% |
| 2025 |
| 12/30 | 159 | 162 | 156 | 156 | -3.11% | 240,200 | 57億5889万 | -6.59% |
| 12/29 | 158 | 168 | 156 | 161 | +5.23% | 681,800 | 59億4347万 | -4.17% |
| 12/26 | 154 | 159 | 153 | 153 | -0.65% | 473,600 | 56億4814万 | -8.93% |
| 12/25 | 150 | 154 | 149 | 154 | +4.05% | 463,700 | 56億8506万 | -8.88% |
| 12/24 | 15:30 事業計画及び成長可能性に関する説明資料 |
| 12/24 | 153 | 154 | 148 | 148 | -3.27% | 535,300 | 54億6356万 | -12.43% |
| 12/23 | 160 | 161 | 150 | 153 | -1.29% | 636,600 | 56億4814万 | -11.05% |
| 12/22 | 162 | 165 | 154 | 155 | -7.19% | 1,113,200 | 57億1795万 | -10.4% |
| 12/19 | 202 | 203 | 163 | 167 | -10.7% | 7,198,600 | 61億6063万 | -3.47% |
| 12/18 | 187 | 187 | 187 | 187 | +36.5% | 89,700 | 68億9843万 | +8.72% |
| 12/17 | 16:00 Talus Bioscience, Inc.との共同研究契約締結のお知らせ |
| 12/17 | 16:00 PRISM BioLab とエーザイが共同創出したE7386、Clinical Cancer Research誌にて非臨床研究結果に関する学術論文が発表される |
| 12/17 | 143 | 144 | 136 | 137 | -3.52% | 575,500 | 50億5393万 | -19.88% |
| 12/16 | 151 | 152 | 142 | 142 | -4.7% | 747,500 | 52億3838万 | -16.96% |
| 12/15 | 152 | 154 | 148 | 149 | -2.61% | 587,100 | 54億9661万 | -12.87% |
| 12/12 | 156 | 157 | 153 | 153 | 0% | 264,100 | 56億4417万 | -10.53% |
| 12/11 | 159 | 161 | 152 | 153 | -3.77% | 553,100 | 56億4417万 | -10.53% |
| 12/10 | 170 | 171 | 153 | 159 | -5.92% | 1,689,600 | 58億6551万 | -6.47% |
| 12/09 | 179 | 182 | 168 | 169 | -9.14% | 1,397,300 | 62億3441万 | 0% |
| 12/08 | 171 | 195 | 171 | 186 | +5.08% | 2,466,800 | 68億6154万 | +10.71% |
| 12/05 | 176 | 180 | 166 | 177 | -1.12% | 1,395,500 | 65億2953万 | +5.99% |
| 12/04 | 180 | 189 | 178 | 179 | -2.72% | 1,339,600 | 66億331万 | +7.83% |
| 12/03 | 189 | 200 | 176 | 184 | -6.12% | 3,949,400 | 67億8776万 | +11.52% |
| 12/02 | 242 | 279 | 189 | 196 | -13.27% | 14,129,600 | 72億3044万 | +19.51% |
| 12/01 | 190 | 230 | 182 | 226 | +25.56% | 11,520,700 | 83億3714万 | +38.65% |
| 11/28 | 16:30 PRISM BioLab、PepMetics化合物の新規二環性化合物の特許取得のお知らせ |
| 11/28 | 173 | 183 | 173 | 180 | +4.05% | 262,900 | 66億4020万 | +11.8% |
| 11/27 | 176 | 180 | 167 | 173 | -1.7% | 388,400 | 63億8197万 | +7.45% |
| 11/26 | 173 | 179 | 173 | 176 | -0.56% | 248,100 | 64億9264万 | +9.32% |
| 11/26 | 8:00 2025年９月期 決算説明会 ログミーFinance書き起こし記事公開のお知らせ |
| 11/25 | 167 | 179 | 165 | 177 | +4.73% | 436,500 | 65億2953万 | +9.94% |
| 11/21 | 17:00 役員人事に関するお知らせ |
| 11/21 | 163 | 170 | 160 | 169 | +0.6% | 275,100 | 62億3441万 | +5.63% |
| 11/20 | 170 | 173 | 165 | 168 | -1.18% | 656,900 | 61億8408万 | +5% |
| 11/19 | 197 | 200 | 170 | 170 | -16.67% | 1,906,900 | 62億5770万 | +6.25% |
| 11/18 | 16:30 2025年9月期決算説明会資料 |
| 11/18 | 188 | 212 | 176 | 204 | +1.49% | 5,345,900 | 75億924万 | +28.3% |
| 11/17 | 171 | 201 | 157 | 201 | +33.11% | 9,657,300 | 73億9881万 | +27.22% |
| 11/14 | 16:30 2025年9月期決算短信〔日本基準〕(非連結) |
| 11/14 | 16:30 営業外収益及び特別損失の計上に関するお知らせ |
| 11/14 | 16:30 小野薬品工業株式会社との創薬提携における初回マイルストン達成並びに一時金受領のお知らせ |
| 11/14 | 150 | 152 | 146 | 151 | +3.42% | 135,200 | 55億5831万 | -3.82% |
| 11/13 | 145 | 146 | 144 | 146 | -0.68% | 27,700 | 53億7426万 | -7.59% |
| 11/12 | 145 | 148 | 144 | 147 | +0.68% | 52,700 | 54億1107万 | -6.96% |
| 11/11 | 145 | 150 | 145 | 146 | +0.69% | 84,500 | 53億7426万 | -8.18% |
| 11/10 | 141 | 145 | 141 | 145 | +2.84% | 327,600 | 53億3745万 | -9.38% |
| 11/07 | 141 | 145 | 140 | 141 | -3.42% | 83,200 | 51億9021万 | -12.42% |
| 11/06 | 137 | 147 | 137 | 146 | +6.57% | 177,700 | 53億7426万 | -9.88% |
| 11/05 | 136 | 139 | 132 | 137 | 0% | 278,900 | 50億4297万 | -15.95% |
| 11/04 | 16:00 2025年９月期決算説明会のお知らせ |
| 11/04 | 150 | 150 | 136 | 137 | -8.05% | 609,500 | 50億4297万 | -16.46% |
| 10/31 | 145 | 151 | 145 | 149 | +1.36% | 79,000 | 54億8469万 | -10.24% |
| 10/30 | 153 | 155 | 145 | 147 | -3.92% | 330,500 | 54億1107万 | -11.98% |
| 10/29 | 162 | 162 | 152 | 153 | -5.56% | 244,300 | 56億3193万 | -8.93% |
| 10/28 | 167 | 167 | 161 | 162 | -1.82% | 95,300 | 59億6322万 | -4.14% |
| 10/27 | 165 | 170 | 164 | 165 | -0.6% | 101,000 | 60億7365万 | -2.37% |
| 10/24 | 170 | 170 | 166 | 166 | -1.19% | 47,600 | 61億1046万 | -1.78% |
| 10/23 | 173 | 174 | 168 | 168 | -4% | 69,100 | 61億8408万 | -1.18% |
| 10/22 | 174 | 177 | 173 | 175 | 0% | 72,300 | 64億4175万 | +2.94% |
| 10/21 | 167 | 177 | 166 | 175 | +2.94% | 285,000 | 64億3825万 | +3.55% |
| 10/20 | 167 | 171 | 159 | 170 | +6.25% | 474,000 | 62億5430万 | +0.59% |
| 10/17 | 18:00 PRISM BioLabとエーザイが共同創出したE7386、エーザイが欧州臨床腫瘍学会（ESMO）年次総会にて臨床試験結果とバイオマーカー探索結果発表 |
| 10/17 | 165 | 165 | 159 | 160 | -3.61% | 137,900 | 58億8640万 | -5.88% |
| 10/16 | 165 | 168 | 163 | 166 | +0.61% | 37,800 | 61億714万 | -2.92% |
| 10/15 | 164 | 166 | 159 | 165 | +1.85% | 98,900 | 60億7035万 | -3.51% |
| 10/14 | 170 | 170 | 160 | 162 | -7.43% | 312,600 | 59億5998万 | -5.81% |
| 10/10 | 169 | 176 | 167 | 175 | +2.94% | 104,400 | 64億3825万 | +1.16% |
| 10/09 | 167 | 171 | 164 | 170 | +2.41% | 162,500 | 62億5430万 | -1.73% |
| 10/08 | 169 | 175 | 164 | 166 | -0.6% | 281,600 | 61億714万 | -4.6% |
| 10/03 | 16:00 LES LABORATOIRES SERVIERとの共同研究契約の終了に関するお知らせ |
| 10/01 | 16:45 PRISM BioLab、PepMetics化合物の新規二環性化合物の特許取得のお知らせ |
10年以上蓄積したファイナンスデータとAIを掛け合わせて、投資の意思決定を加速させるポジションです。
